Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. - Wikidata - awgldk - TriplyDB

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

http://www.wikidata.org/entity/Q33369628

about

Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment Radiotherapy and "new" drugs-new side effects?Molecular biology of gliomas: present and future challenges Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Present and potential future issues in glioblastoma treatment.Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Therapeutic strategies for inhibiting invasion in glioblastoma.Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.Progress on antiangiogenic therapy for patients with malignant glioma.Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.Molecular targeting of glioblastoma: Drug discovery and therapies Experimental approaches for the treatment of malignant gliomas.Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.Pharmacokinetic interactions with antiepileptic drugs: always the bad actor or simply misunderstood?Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas Impact of imaging measurements on response assessment in glioblastoma clinical trials Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.Genome-wide associations of signaling pathways in glioblastoma multiforme Imatinib mesylate plus hydroxyurea chemotherapy for cerebellar meningioma in a Belgian Malinois dog.Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.Drug development in oncology: classical cytotoxics and molecularly targeted agents.Canadian recommendations for the treatment of glioblastoma multiforme.CNS Anticancer Drug Discovery and Development Conference White Paper.Activation of abl family kinases in solid tumors.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Chemotherapy in the treatment of malignant gliomas.Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.Blood-brain barrier and chemotherapeutic treatment of brain tumors.Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma Inhibiting kinases in malignant gliomas.Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.Molecularly targeted therapies for malignant gliomas: advances and challenges.Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.

P2860

Q26785952-2CC457EC-EB32-45D5-AC6B-52A72523B413 Q26861498-891A5FAF-4071-4EF1-8329-714AAF3F1174 Q27001295-F82D3C23-18FB-40E8-BBA1-D0CFE6B44E6E Q30250273-9D0388C0-8776-40A2-A46B-2ECEBBC58236 Q31043603-2E6A783E-AFB9-40D4-B23D-16ACA08FD4B8 Q33304051-70C83EDF-5EA8-4FD4-B517-90CC036F5891 Q33387009-CAD4ECD7-E4E9-4EFB-AF58-ED9BEA9D13DF Q33390267-CD8A6E67-0DA1-492E-A9D4-3FC3531FD1CC Q33399939-363C490C-6702-4828-9CD1-2A0D017E9853 Q33426563-AF69A50C-77B2-43C4-82D5-40459A46AC68 Q33574578-5049A289-EDA7-419F-A087-094F4652719B Q33576476-6BAE3900-E1CF-4F17-9F6B-5381930D9AAC Q33773189-75C07D64-CB14-4106-B307-B269B826213B Q33853600-5833598A-6D94-4992-BC27-11AA4075126C Q33911283-AB1305C8-6655-4371-B7A1-D1879AC1450A Q34127138-FEC5E58C-F4DC-4A41-BA8A-8BF340E8FB04 Q34132781-DBF75052-DCF2-4499-88D8-1E152755AE8D Q34183961-595B9678-C9BD-49B6-9072-1AD1AA6193EF Q34191508-04B729B8-0540-4648-A1FD-B3C9CCC5BA79 Q34231554-4B9AF574-ADE2-481F-ADFC-5A278F6964DA Q34331328-F9C767D6-5434-4FAB-9E8B-54999C0774E8 Q34580581-4D2DFA8E-8D94-480F-AEF7-D35FEF6A158B Q34640446-2EF20B78-866C-496B-8DBD-F5267D38F1F1 Q34749804-90A49ACA-088C-4B29-93FF-41088F512151 Q35008709-5D2E5062-B465-4A0C-880B-0ACA670B310D Q35440540-70665F38-E57E-4C0E-838C-879A8B5F2011 Q35827606-78323814-0E27-4D39-B196-30064DB469B1 Q35855352-79F8A117-FF25-48E9-941D-C9557FBDC064 Q36089590-792D6D0C-3226-45A6-9251-8E2847D21804 Q36443421-9E9B520A-C57F-4FC6-9F94-1F1CB717A984 Q36499234-903A99FC-ABA9-422E-AA51-B91AE6DB22B5 Q36499238-A029720E-BF86-431A-94C3-365C4A584953 Q36544472-E6E6001F-DDE3-4D25-B479-AB15056B6407 Q36558683-CF94285E-0621-4CD2-BEE6-44526FD8DDBA Q36668246-DFFEE018-4303-43EE-AA2D-B9EB92D2FEC0 Q36740517-BF865684-2194-4ECF-A11F-061AF2A6B28E Q36764876-98A44463-F0E9-478A-9DFE-1C8531732587 Q36792630-2B37350C-139B-4BE8-9643-FA57A534B936 Q36817109-A365B3A8-EFF2-4523-BD84-717561753BF1 Q36872284-5AD8457D-6BBF-4728-86E0-47E30084E4E1

P2860

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

http://www.wikidata.org/entity/Q33369628

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase II study of imatinib mes ...... rrent glioblastoma multiforme.

@ast

Phase II study of imatinib mes ...... rrent glioblastoma multiforme.

@en

type

label

Phase II study of imatinib mes ...... rrent glioblastoma multiforme.

@ast

Phase II study of imatinib mes ...... rrent glioblastoma multiforme.

@en

prefLabel

Phase II study of imatinib mes ...... rrent glioblastoma multiforme.

@ast

Phase II study of imatinib mes ...... rrent glioblastoma multiforme.

@en

P1433

Q33369628-3BDC49C8-6497-46E5-8547-DC6D37BE4C6A

P1476

Q33369628-2A3349CA-51C7-433B-BAEC-CAE9D4F48E67

P2093

Q33369628-034D3A8E-8A52-48F5-AD99-55EF1572F00A

Q33369628-4682C2BF-9CA1-43B7-A3A8-3D463DE414B6

Q33369628-4C951A66-B785-4D3F-B322-C9DE723D9BEA

Q33369628-617A1D43-469B-420B-A9FE-AAC3864472DB

Q33369628-753BE525-1D61-4AEF-AFC7-9DEB490C0F21

Q33369628-7C7F72E8-EF13-4FE1-9932-9DE7B7A18B0B

Q33369628-7D8F0233-E123-451C-8019-302D445E77FC

Q33369628-8F4F805F-F6A4-41E8-B493-1315D08BF5C7

Q33369628-9C080FA2-AC1F-45C2-8D17-8BADD6E1DB3A

Q33369628-A1C2DADB-83F0-419F-A57E-A53FD4D7F4D7

P304

Q33369628-A12E989D-2411-4309-9A5E-FB94C37FACE6

P31

Q33369628-958D6115-054A-41C6-A434-6A5FCE34DAED

P356

Q33369628-BE4FF86E-EBBF-46B2-894A-956E15FDDBC5

P407

Q33369628-6CDD27CF-4412-4B8A-86CD-AD7F64C9024A

P433

Q33369628-91BBBAE7-E898-4FA5-95E7-248468F1941F

P478

Q33369628-6F51E50F-F882-4AA3-B22B-568911F0E754

P50

Q33369628-01310E38-4CE9-472E-BFBF-9701FF35EF46

Q33369628-1383A6DF-CCA6-416A-BC07-556266FD2A7E

Q33369628-3EF0E989-85E3-42F0-879B-08A9AB5821D6

Q33369628-3F79071E-42D3-4AE9-89D6-95853B12ECBA

Q33369628-A0AE024F-FCBB-4968-888A-F722C05DCD84

Q33369628-CFB32F83-72A1-4084-8DFA-E536DCBC8A81

P577

Q33369628-BAEFA0DB-B589-4C65-9B7A-0EAE2AA944D1

P698

Q33369628-41808D5C-167A-4B20-9675-9BE0E1D9DC60

P356

JCO.2005.03.2185

P1433

Journal of Clinical Oncology

P1476

Phase II study of imatinib mes ...... rrent glioblastoma multiforme.

@en

P2093

August J Salvado

http://www.w3.org/2001/XMLSchema#string

Gregor Dresemann

http://www.w3.org/2001/XMLSchema#string

James E Herndon

http://www.w3.org/2001/XMLSchema#string

James J Vredenburgh

http://www.w3.org/2001/XMLSchema#string

James M Provenzale

http://www.w3.org/2001/XMLSchema#string

Jeannette M Dowell

http://www.w3.org/2001/XMLSchema#string

Jennifer A Quinn

http://www.w3.org/2001/XMLSchema#string

Jeremy N Rich

http://www.w3.org/2001/XMLSchema#string

John H Sampson

http://www.w3.org/2001/XMLSchema#string

Kimberly P Kicielinski

http://www.w3.org/2001/XMLSchema#string

P304

9359-9368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.03.2185

http://www.w3.org/2001/XMLSchema#string

P407

P433

36

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Henry Seth Friedman

Annick Desjardins

Sridharan Gururangan

David A Reardon

Roger E McLendon

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16361636

http://www.w3.org/2001/XMLSchema#string